Publications

Kiely B, Travado L, Smith AL, Timeus IA, Kim SB, Haidinger R, N M Nanre N, Rugo H, Attfield G, Lewis A, Cardoso F. Increasing awareness of and referral to support services in advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 7). Breast (Edinburgh, Scotland). 2025. PMID: 41298009

Shah NJ, Shinde R, Bhattacharya R, LeMasters T, Ning N, Schmier J, Tan M, Vickery D, Perini R, Motzer RJ. Postimmunotherapy and Vascular Endothelial Growth Factor Inhibitor Landscape in Advanced Renal Cell Carcinoma: Treatment Patterns, Costs, and Outcomes. JCO oncology practice. 2025. PMID: 41082704

Oseran AS, Aggarwal R, Wadhera RK. Cardiovascular Risk Factor Management in Medicare Advantage and Traditional Medicare. Circulation. Cardiovascular quality and outcomes. 2025. PMID: 41064875

Manabe T, Bergo HC, Li Q, Wang TS, Severson P, Miller N, Lee C, Donderici EY, Zhang N, Wu W, Chou YT, Kerr DL, Allegakoen P, Grandinetti KB, Soroceanu L, Pelham RJ, Martin ES, Murphy EA, Khanna V, Neal JW, Chen CT, Kato S, Williams R, Bivona TG. Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies. Research square. 2025. PMID: 41282105

Bardossy ES, Bergmann L, Henrion-Lacritick A, Nigg J, Correy GJ, Ashworth A, Fraser JS, Saleh MC. Macrodomain ADP-ribose binding but not ADP-ribosylhydrolase activity is critical for chikungunya virus infection of Aedes mosquitoes. bioRxiv : the preprint server for biology. 2025. PMID: 41279946

Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP, Panelists of the St. Gallen International Breast Cancer Consensus 2025. Electronic address: https://, Panelists of the St. Gallen International Breast Cancer Consensus 2025. Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2025. PMID: 41072918

Modi S, Jacot W, Iwata H, Park YH, Vidal Losada M, Li W, Tsurutani J, Ueno NT, Zaman K, Prat A, Papazisis K, Rugo HS, Yamashita T, Harbeck N, Im SA, De Laurentiis M, Pierga JY, Wang X, Gombos A, Tokunaga E, Orbegoso Aguilar C, Yung L, Xiao F, Cheng Y, Cameron D. Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nature medicine. 2025. PMID: 41062831

Keenan BP, Qiao G, Kunda N, Kone L, Guldberg SM, Todeschini L, Kumar P, Pollini T, Hernandez S, Qin J, Fong L, Spitzer MH, Prabhakar BS, Maker AV. Combination LIGHT overexpression and checkpoint blockade disrupts the tumor immune environment impacting colorectal liver metastases. Science advances. 2025. PMID: 41061056

Bidard FC, Gessain G, Bachelot T, Frechin L, Vincent-Salomon A, Drubay D, Lemonnier J, Walter T, Penault-Llorca F, Martin AL, Gaudin C, Bichat A, Sassi F, Berlemont S, Chavez-MacGregor M, Rugo HS, Badoual C, Pistilli B, Ribeiro J, Di Meglio A, Lacroix-Triki M, Luis IV, Lerousseau M, André F. Erratum: Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 41056514

Borgers JSW, Johnson DB, Livingstone E, Schadendorf D, Buchbinder EI, Haydu LE, Gohil L, Robinson WA, Mehmi I, Hamid O, Ferreira M, Salama AKS, Dimitriou F, Carlino MS, Long GV, Ascierto PA, Simeone E, Najjar YG, Hospers GAP, Choi J, Chandra S, Wayne JD, García CIR, Xu W, Lebbé C, Da-Meda L, Atkinson V, Mckean M, Forschner A, Asare EA, Daletzakis A, Taylor JS, Amant F, Tsai KK, Eroglu Z, Haanen JBAG, Glitza de Oliva IC. Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study. EClinicalMedicine. 2025. PMID: 41127564

Johanna Balas, Lauren Bowling, Nonna Shakhnazaryan, Rahul Raj Aggarwal, Hala Borno, Julian C. Hong, Franklin W. Huang, Barry Tong, Daniel H. Kwon. Evaluating an artificial intelligence (AI) communication platform for racial biases in information quality about prostate cancer (PCa) germline testing. JCO oncology practice. 2025. PMID:

Schram AM, Naqash AR, Haura EB, Riess JW, Ulahannan SV, Ou SI, Munster PN, Cheng ML, Gustafson WC, Bitman B, Friedman R, Penn R, Kar S, Seshadri V, Wang Z, Tao L, Yang YC, Singh M, Burris HA, Meyerowitz JG. The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 41056387

Blaisdell A, Bachl S, Sandoval LR, Ching C, Bowman CJ, Kale N, Prabandham M, Diolaiti M, Havig C, Advincula R, Lenci N, Li Z, Yamashita E, Wang CH, Zhang S, Liu Q, Achacoso P, Stibor D, Øynebråten I, Seo J, Ashworth A, Marson A, Ye CJ, Malynn BA, Eyquem J, Carnevale J, Ma A. Base-editing a single missense mutation in A20 enhances CAR-T cell efficacy. bioRxiv : the preprint server for biology. 2025. PMID: 41446213

Foster L, Anderson LD, Chung A, Chaulagain CP, Pettijohn E, Cowan AJ, Costello C, Larson S, Sborov DW, Shain KH, Silbermann R, Voorhees P, Krevvata M, Pei H, Patel S, Khare V, Cortoos A, Carson R, Lin TS, Badros A. Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses. Blood cancer journal. 2025. PMID: 41053004

Yamamoto K, Bando H, Misumi T, Nishikawa T, Wakabayashi M, Yamazaki K, Maehara Y, Oki E, Saltz LB, Douillard JY, Punt CJ, Koopman M, Van Cutsem E, Bokemeyer C, Venook AP, Heinemann V, Cremolini C, Randolph Hecht J, Schmoll HJ, Nakayama G, Lenz HJ, Andre T, Shi Q, de Gramont A, Shitara K, Yoshino T. Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study. European journal of cancer (Oxford, England : 1990). 2025. PMID: 41056789

Parikh RB, Iasonos A, Ko A, Warner J, Miller K, Friedberg JW. Bringing Trustworthy Artificial Intelligence to the Clinical Forefront at JCO: A Guide for Studies Testing Artificial Intelligence Models. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 41037760

Nizam A, Nguyen CB, Li J, Zabor EC, Msaouel P, Jiang CY, Alhalabi O, Oh E, Davidsohn MP, Epstein IB, Bakaloudi DR, Talukder R, Jindal T, Taylor AK, Glover MJ, Khaki AR, Lemke E, Mabey H, Abuqayas B, Jang A, Brown JR, Evans ST, Pywell C, Basu A, Bilen MA, Barata PC, Zakharia Y, Milowsky MI, Kilari D, Hoimes CJ, Shah SA, Emamekhoo H, Davis NB, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS. Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study. Cancer medicine. 2025. PMID: 41031719

T. Brown, M. Gubens, C. Mulvey, J. Kratz, J. Rotow, T. Patil, J. Riess, C. Blakely. P1.07.40 Detection of ctDNA Prior to Neoadjuvant Osimertinib Treatment Correlates With Decreased EFS in EGFR-Mutated NSCLC. Journal of Thoracic Oncology. 2025. PMID:

Loren AW, Mielcarek M, Bolaños-Meade J, Brammer J, Cowden M, Di Stasi A, El-Jawahri A, Elmariah H, Gundabolu K, Gutman J, Ho V, Hoeg RT, Horwitz M, Jamy O, Kassim A, Kharfan-Dabaja M, Lee L, Logan A, Luszcak C, Magenau JM, Martin TG, Mittal V, Moreira J, Muffly L, Nakamura R, Nawas M, Nieto Y, Ninos C, Oliai C, Papanicolaou G, Pidala J, Randolph B, Schroeder MA, Tessier J, Topal J, Tzachanis D, Varshavsky-Yanovsky AN, Jones F, Stehman K. Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2025. PMID: 41067275

Rahmani R, Kang H, Chan JW. A Patient With Prior Skin Cancers and New Diagnosis of Bell Palsy. JAMA oncology. 2025. PMID: 40773185